<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="the virus present in the respiratory tract despite oseltamivir and" exact="peramivir" post="treatment. Through the neuraminidase inhibition assay, both viruses were"/>
 <result pre="variation S31N in the matrix gene, the M2 proton-channel blockers" exact="amantadine" post="and rimantadine are no longer clinically applied [4]. The"/>
 <result pre="in the matrix gene, the M2 proton-channel blockers amantadine and" exact="rimantadine" post="are no longer clinically applied [4]. The Korea Centers"/>
 <result pre="with acute hematologic cancer not exhibiting recovery despite oseltamivir and" exact="peramivir" post="administration; these were characterized genetically and antigenically following isolation."/>
 <result pre="out using the Agpath ID One-step RT-PCR system (Applied Biosystems," exact="Foster" post="City, CA, USA) [10]. TableÂ 1 lists multiplex (A/B/IPC"/>
 <result pre="influenza viruses to NAI was characterized using oseltamivir, zanamivir, and" exact="peramivir" post="at concentrations that inhibited the NA activity by 50%"/>
 <result pre="and A/Korea/S0002/2019 viruses exhibited significantly reduced inhibition by oseltamivir and" exact="peramivir" post="with &amp;gt;â€‰100 IC50 fold-changes relative to drug-sensitive virus, but"/>
 <result pre="fold-changes relative to drug-sensitive virus, but were normally susceptible to" exact="zanamivir" post="(TableÂ 6). However, every isolate collected from the KINRESS"/>
 <result pre="Virus Type (Subtype) Genotype NAI resistance (IC50 fold change) Oseltamivir" exact="Zanamivir" post="Peramivir A/Korea/S0003/2019 A(H1N1)pdm09 Variant (H275Y) HRI 179.33 NI 2.56"/>
 <result pre="Type (Subtype) Genotype NAI resistance (IC50 fold change) Oseltamivir Zanamivir" exact="Peramivir" post="A/Korea/S0003/2019 A(H1N1)pdm09 Variant (H275Y) HRI 179.33 NI 2.56 HRI"/>
 <result pre="the IC50 for oseltamivir and peramivir, but not zanamivir. Thus," exact="zanamivir" post="might be an option for immunocompromised patients when oseltamivir"/>
 <result pre="might be an option for immunocompromised patients when oseltamivir and" exact="peramivir" post="are not effective. These findings also indicate the necessity"/>
 <result pre="Respiratory Viruses Surveillance System SARI Severe Acute Respiratory Infection H" exact="Histidine" post="Y Tyrosine NAIs Neuraminidase inhibitors NA Neuraminidase HA Hemagglutinin"/>
 <result pre="immunocompromised vs nonimmunocompromised hostsClin Infect Dis20135821422410.1093/cid/cit72524186906 19.TrebbienRPedersenSSVorborgKFranckKTFischerTKDevelopment of oseltamivir and" exact="zanamivir" post="resistance in influenza a (H1N1) pdm09 virus, Denmark, 2014Euro"/>
</results>
